Active, not recruitingPhase 2NCT06315426

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Studying Polyrrhinia

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Principal Investigator: Zheng Liu, PHD
Tongji Hospital
Intervention: GR1802 injection(biological)
Enrollment: 240 target
Eligibility: 18-75 years · All sexes
Timeline: 2024 – 2025

Study locations (15)

Hebei Petro China Central Hospital, Langfang, Hebei, China
Central Hospital of Qinghe County, Xingtai, Hebei, China
Zhengzhou Central Hospital, Zhengzhou, Henan, China
Jingzhou Central Hospital, Jingzhou, Hubei, China
The Central Hospital of Wuhan, Wuhan, Hubei, China
Wuhan Union Hospital of China, Wuhan, Hubei, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Shandong Second Provincial General Hospital, Jinan, Shandong, China
Liaocheng People's Hospital, Liaocheng, Shandong, China
Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China
First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
Shanxi Bethune Hospital, Taiyuan, Shanxi, China
Xi'an Daxing Hospital, Xi’an, Shanxi, China
Yuncheng Central Hospital, Yuncheng, Shanxi, China
Chengdu Second People's Hospital, Chengdu, Sichuan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06315426 on ClinicalTrials.gov

Other trials for Polyrrhinia

Additional recruiting or active studies for the same condition.

See all trials for Polyrrhinia →

← Back to all trials